Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29 Highly statistically significant results on all secondary efficacy endpoints ...
* ACLARIS THERAPEUTICS’ A-101 45% TOPICAL SOLUTION MEETS PRIMARY AND ALL SECONDARY ENDPOINTS IN TWO PHASE 2 CLINICAL TRIALS FOR COMMON WARTS * ACLARIS THERAPEUTICS - POSITIVE RESULTS FROM 2 PHASE 2 ...
Approval paves the way for decentralized regulatory process in other European countries. The German regulatory authorities approved MediGene’s topical genital warts treatment, Veregen®. Approval ...
Background: Topical 0.12% chlorhexidine has been used widely to prevent ventilator-associated pneumonia in patients undergoing mechanical ventilation. However, it is not approved for mucosal ...
Hosted on MSN
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts
Shares of Ligand Pharmaceuticals and Pelthos Therapeutics rose on Thursday after the commercial launch of Zelsuvmi (berdazimer) topical gel, developed under their partnership, to treat a common viral ...
Aclaris Therapeutics announced positive results from a phase 3 trial investigating a proprietary formulation of hydrogen peroxide (A-101) for the topical treatment of common warts. Aclaris ...
Facial wart on a child. Oral isotretinoin showed the best response in cases of facial warts (HealthDay News) — Oral isotretinoin shows a better and earlier response than topical isotretinoin for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback